Ruconest (C1 Esterase Inhibitor [recombinant])

Ruconest is a recombinant C1 esterase inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE). Mechanism: C1 esterase inhibitor is a complement protein regulating the kallikrein–bradykinin pathway. Deficiency or dysfunction leads to recurrent angioedema in HAE. Clinical relevance: HAE is a rare, life-threatening disorder characterized by swelling in extremities, GI tract, face, and airway, with risk of asphyxiation. FDA Indication: Treatment of acute attacks of HAE in patients ≥13 years. <a id="